drugset / Trial / NCT05160922
Crizotinib Continuation Clinical Study
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.
Timeline
- Start
- 2021-12-27
- Primary completion
- 2028-03-21
- Completion
- 2028-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crizotinib | Small molecule | — | Oral |